A hard look at a quiet crisis in women's health
What if a routine medical procedure, meant to prevent danger, ends up opening a wider door of risk? That question sits at the heart of a pressing health conversation in Australia around Asherman’s syndrome, a condition many have never heard of until it disrupts a woman’s ability to conceive after a D&C, or dilation and curettage. The procedure is supposed to clear tissue after miscarriage, abortion, or delivery, but for a not-insignificant minority it leaves behind scar tissue that can derail fertility and complicate pregnancies for years to come. Personally, I think this is a stark reminder that medical routines can carry overlooked collateral damage, especially when power dynamics and data gaps silence patient voices.
A flawed default, with lasting consequences
What makes this topic particularly potent is not just the medical science, but the social signal it sends about how health systems treat women’s bodies. The basic reality is simple: when a D&C is performed, a small but real risk exists of uterine scarring. What’s alarming is how the storytelling around that risk often remains underplayed, and in some cases, minimized. From my perspective, acknowledging risk openly is not alarmism; it’s accountability. The story of Lily Johnstone and Naomi Cate illustrates this tension in granular, human terms: two women, each with plans for motherhood, both confronted with outcomes shaped by how the procedure was executed and how information was communicated before consent.
The tools matter: a 19th-century instrument in a modern clinic
One of the most striking and troubling facts is the ongoing use of sharp curettes—looped metal devices dating back to the 1840s—despite recommendations to switch to suction, blunt curettes. What makes this particularly fascinating is how a technology that predated anesthetics, antiseptics, and even modern imaging remains embedded in contemporary clinical practice. In my opinion, this isn’t just about equipment; it’s about culture, incentives, and the friction between tradition and evidence-based care. A tool designed as a diagnostic aid for tissue sampling can inadvertently become a driver of harm when used to treat a condition it wasn’t intended to manage. The implication is clear: outdated tools perpetuate risk, and mercy here isn’t a matter of opinion but patient safety.
Guidelines exist, but implementation lags
RANZCOG’s guidelines in 2023-24 called for avoiding sharp curettes in miscarriage-related D&Cs, with a clear hope that suction curettes would become the default. Yet the absence of comprehensive rules for postpartum D&Cs, limited ultrasound access in some theatres, and uneven training create a patchwork of practice that leaves real people vulnerable. What this reveals is a broader pattern: policy documents can exist in a vacuum without concerted, data-driven enforcement. From my point of view, guidelines without robust oversight become decorative promises that fail when the patient lies on the table.
Consent and communication under strain
Several accounts in the material point to a second, quieter failure: informed consent. If a patient signs off on a procedure with the assurance that a suction curette will be used, only to discover a sharp curette was employed, that erodes trust and compounds harm. That breach isn’t just a legal hazard; it’s a breach of care. What many people don’t realize is how consent operates under the pressure of emotion and urgency. A patient’s ability to parse medical jargon or to recall the relative risk of complications can be compromised when a clinician is juggling time, supply constraints, and a chaotic clinical environment. If consent becomes a checkbox rather than a conversation, the door opens to misalignment between patient values and clinical choices.
Data deserts and the need for a registry
Another recurring theme is the lack of reliable data. Without a national or even regional registry of Asherman’s cases and D&C outcomes, the medical community lacks a clear map of where harm clusters, which patient groups are most at risk, and how often outdated instruments are used. A detail I find especially interesting is the argument for ultrasound-guided D&Cs as a standard of care. Ultrasound adds a level of precision that can reduce the chance of residual tissue and, by extension, scarring. But access to ultrasound in every operating room, and training clinicians to use it effectively, is not a trivial fix. It requires investment, logistics, and a shift in how hospitals prioritize equipment and training budgets.
Rhetoric versus reality in regulation
There’s a mismatch between regulatory posture and lived experience. The Therapeutic Goods Administration classifies sharp curettes as class 1 devices, which does not mandate adverse incident reporting. That regulatory stance has real-world consequences: if adverse events aren’t systematically reported, regulators can’t see the full picture. Politically charged commentary notwithstanding, this is a practical failure: governance relies on data. If policymakers are serious about reducing preventable harm, they must demand better reporting, tighten device classifications when risk is demonstrable, and create clear triggers for mandatory incident alerts. From my vantage point, this is not a radical reform but a commonsense upgrade to patient protection.
The human cost behind statistics
Behind every statistic about incidence and risk are individuals who bear long, painful consequences. Naomi Cate’s story—travelling across the country for corrective surgery, delaying pregnancy, and living with the knowledge that a different tool could have spared her—highlights the emotional toll. It’s not merely about fertility; it’s about autonomy, trust, and the right to feel safe in a clinical setting. This is where the editorial lens must sharpen: numbers tell a story, but people tell the moral of the story. And the moral is that precision, transparency, and accountability aren’t optional extras in women’s health; they’re essential.
Where this could go next
Looking ahead, a few trends seem likely and worth discussing publicly:
- Standardizing ultrasound-assisted D&Cs across all settings, with mandated training and equipment upgrades where needed.
- Establishing a national or regional Asherman’s registry to track outcomes, facilitate research, and inform guidelines with real-world data.
- Reframing consent as an ongoing conversation, with explicit disclosures about the risk of scarring, especially when multiple D&Cs are contemplated during a single pregnancy.
- Revisiting device classifications to ensure that adverse events trigger appropriate regulatory scrutiny rather than waiting for a litigation-driven wake-up call.
What this all signals is a broader question about medical progress and patient protection. If a century-old instrument still shapes the risk profile of a common procedure, then the medical community has not fully modernized its practice. What this really suggests is that clinical progress is not just about new drugs or technologies; it’s about retiring outdated habits, investing in safer workflows, and treating patients as co-owners of the care journey.
Final thought: a call to action for systems that finally listen
In my opinion, the right response to these stories is not despair but a functional blueprint for change. Health systems should insist on ultrasound-guided D&Cs as the default where possible, publish transparent data on instrument usage and outcomes, and create patient-centered consent processes that accurately reflect risk and alternatives. A stronger regulatory backbone paired with real-world data can turn a painful lesson into a safeguard for future patients. If we can translate these insights into concrete standards and better funding for research, the next generation of mothers may not have to choose between hope and risk—their care can be safer, more transparent, and more responsive to their lived realities.
